Home › Drugs by Condition › R › Renal Cell Carcinoma › Temsirolimus Pregnancy Warnings
Print Save or Share

Temsirolimus Pregnancy and Breastfeeding Warnings

Temsirolimus is also known as: Torisel

Overview

Temsirolimus may cause harm to the fetus. Do not become pregnant while you are using it and for 3 months after you stop Temsirolimus. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Temsirolimus while you are pregnant. It is not known if Temsirolimus is found in breast milk. Do not breast-feed while taking Temsirolimus.

Temsirolimus Pregnancy Warnings

Temsirolimus has been assigned to pregnancy category D by the FDA. Animal studies have revealed that temsirolimus administered daily as an oral formulation caused embryo-fetal and intrauterine toxicities at human subtherapeutic exposures. There are no controlled data in human pregnancy. Temsirolimus should only be given during pregnancy when there are no alternatives and benefit outweighs risk.

Women of childbearing potential should be advised to avoid becoming pregnant throughout treatment and for three months after temsirolimus therapy has stopped. Temsirolimus can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Female animal studies have reported an increased incidence of pre- and post-implantation losses at oral doses greater than or equal to 4.2 mg/m2/day resulting in decreased numbers of live fetuses. Men should be counseled regarding the effects of temsirolimus on the fetus and sperm prior to starting treatment. Men with partners of childbearing potential should use reliable contraception throughout treatment and are recommended to continue this for three months after the last dose of temsirolimus. Male animal studies have reported the following fertility effects: decreased number of pregnancies, decreased sperm concentration and motility, decreased reproductive organ weights, and testicular tubular degeneration. These effects were observed at oral temsirolimus doses greater than or equal to 3 mg/m2/day. Fertility was absent at 30 mg/m2/day.

Temsirolimus Breastfeeding Warnings

There are no data on the excretion of temsirolimus into human milk. Because many drugs are excreted into human milk and because of the potential for tumorigenicity shown for sirolimus (the active metabolite of temsirolimus) in animal studies, the manufacturer recommends that a decision be made whether to discontinue nursing or to discontinue sirolimus, taking into account the importance of the drug to the mother.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

(web3)